Inhibikase Therapeutics (IKT) Capital Expenditures (2022 - 2025)
Inhibikase Therapeutics (IKT) posted quarterly Capital Expenditures of $13399.0 for Q1 2025, down 93.31% quarter-over-quarter from $200166.0 in Q3 2022.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Capital Expenditures (2022 - 2025) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Capital Expenditures for 2 consecutive years, with $13399.0 the latest figure, recorded in Q1 2025.
- In Q1 2025, Capital Expenditures changed N/A year-over-year to $13399.0; the TTM figure through Dec 2025 stood at $13399.0 (changed N/A YoY), while the FY2025 annual figure was $13399.0, changed N/A from the prior year.
- Capital Expenditures eased to $13399.0 in Q1 2025 per IKT's latest filing, from $200166.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $200166.0 in Q3 2022 and bottomed at $13399.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - | - |